RP-HPLC METHOD DEVELOPMENT AND VALIDATION FOR The ESTIMATION of REMOAGLYFLOZIN ETABONATE

  • Unique Paper ID: 167748
  • Volume: 11
  • Issue: 4
  • PageNo: 548-555
  • Abstract:
  • Remogliflozin etabonate, a prodrug of gliflozin, is a medication used to treat type 2 diabetes and non-alcoholic steatohepatitis. It inhibits the kidney's SGLT2 protein, reducing glucose reabsorption and increasing urine glucose excretion. This drug is absorbed orally and is converted into its active form, Remogliflozin, which helps lower blood glucose levels. A study aimed to develop a simple, accurate, and suitable reversed-phase high-performance liquid chromatography (RP-HPLC) method for determining Remogliflozin Etabonate in bulk drugs and pharmaceutical formulations. The developed method uses an isocratic program with a mobile phase of Methanol and water at a flow rate of 1.0 ml/min. The analysis was performed on an HPLC system equipped with a UV-visible detector, utilizing Openlab EZ-Chrome Software and a Kromasil C18 column. The results were validated for linearity, accuracy, precision, robustness, limit of detection, and limit of quantification. The method offers advantages such as reproducibility, rapid analysis, simple sample preparation, enhanced selectivity and sensitivity. The method is well-suited for routine analysis of Remogliflozin Etabonate in bulk drugs and pharmaceutical dosage forms in the pharmaceutical industry.

Cite This Article

  • ISSN: 2349-6002
  • Volume: 11
  • Issue: 4
  • PageNo: 548-555

RP-HPLC METHOD DEVELOPMENT AND VALIDATION FOR The ESTIMATION of REMOAGLYFLOZIN ETABONATE

Related Articles